ISG15与乳腺癌

doi:10.3969/j.issn.2095-378X.2022.03.013

摘要/Abstract

摘要： 乳腺癌已成为发病率占首位恶性肿瘤,现今该病诊疗也从传统治疗手段逐步转变为个体化精准治疗。干扰素刺激基因15（interferon- stimulated gene 15, ISG15）与许多恶性肿瘤发生发展相关,且参与肿瘤相关免疫应答、许多化疗药物耐药;促进乳腺癌细胞运动,涉及乳腺癌相关肿瘤免疫及多种信号通路,为乳腺癌治疗提供了新思路。本文综述ISG15的结构功能、与肿瘤的相关性及在乳腺癌研究中的进展。

关键词: ISG15, 乳腺癌, ISGylation, 药物敏感, 肿瘤免疫

Abstract: Breast cancer has become the most common women malignant tumor in the world. Nowadays, the diagnosis and treatment of breast cancer has gradually changed from traditional treatment methods to individualized and precise treatment methods. Interferon-stimulated gene 15 （ISG15） is related to the occurrence and development of many malignant tumors, and participates in tumor-related immune responses and the resistance of many chemotherapeutics. ISG15 can promote breast cancer cell movement, and participate in breast cancer-related tumor immunotherapy and various signaling pathways. These research findings provide new insights for breast cancer treatment. In this paper, the structure and function of ISG15, and its correlation with tumors, especially with breast cancer, were reviewed.

Key words: ISG15, Breast cancer, ISGylation, Chemo sensitivity, Tumor immunity

中图分类号:

R665.8

李文倩, 张东伟. ISG15与乳腺癌[J]. 外科研究与新技术, 2022, 11(3): 193-196.

LI Wenqian, ZHANG Dongwei. ISG15 and breast cancer[J]. Surgical Research and New Technique, 2022, 11(3): 193-196.

参考文献

[1] Françoise V, Zhi W, Commere P, et al.USP18 and ISG15 coordinately impact on SKP2 and cell cycle progression[J]. Sci Rep, 2019, 9(1):4066.
[2] Dzimianski JV, Scholte F, Bergeron É, et al.ISG15: it's complicated[J]. J Mol Biol, 2019, 431(21):4203-4216.
[3] Juncker M, Kim C, Reed R, et al.ISG15 attenuates post-translational modifications of mitofusins and congression of damaged mitochondria in Ataxia Telangiectasia cells[J]. Mol Basis Dis, 2021,1867(6):166102.
[4] Xin BT, Jin G, Fernandez DJ, et al.Total chemical synthesis of murine ISG15 and an activity-based probe with physiological binding properties[J]. Org Biomol Chem, 2019, 17(48): 10148-10152.
[5] Jiang Y, Wang X.Structural insights into the species preference of the influenza B virus NS1 protein in ISG15 binding[J]. Protein Cell, 2019, 10(9): 681-687
[6] Freitas BT, Scholte F, Bergeron R, et al.How ISG15 combats viral infection[J]. Virus Res, 2020, 9(286): 198036.
[7] Burks J, Fleury A, Livingston S, et al.ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression[J]. Cancer Immunol Immun,2019, 68(12): 2029-2039.
[8] Sandy Z, Costa I, Schmidt CK.More than meets the ISG15: Emerging roles in the DNA damage response and beyond[J]. Biomolecules, 2020, 10(11):1557.
[9] Swaim CD, Canadeo LA, Huibregtse JM .Approaches for investigating the extracellular signaling function of ISG15 - ScienceDirect[J]. Methods Enzymol, 2019, 618(1): 211-227.
[10] Liu H, Shi B, Zhang Z, et al.PRRSV vaccine strain-induced secretion of extracellular ISG15 stimulates porcine alveolar macrophage antiviral response against PRRSV[J]. Viruses, 2020, 12(9): 1009.
[11] Xin BT, Jin G, Fernandez DJ, et al.Total chemical synthesis of murine ISG15 and an activity-based probe with physiological binding properties[J]. Org Biomol Chem, 2019,17(48):10148-10152.
[12] Fernández DJ, Hess S, Knobeloch KP.Strategies to target ISG15 and USP18 toward therapeutic applications[J]. Front Chem, 2020, 21(7): 923.
[13] Pacella I, Spinelli F R, Severa M, et al.ISG15 protects human Tregs from interferon alpha nduced contraction in a cell‐intrinsic fashion[J]. Clin Transl Immunology, 2020, 9(12):1221.
[14] Held T, Basler M, Knobeloch K, et al.Evidence for an involvement of the ubiquitin‐like modifier ISG15 in MHC class I antigen presentation[J]. Eur J Immunol, 2021,51(1):138-150
[15] Lius S, Karaganiss S, Mo RF, et al.IFNβ treatment inhibits nerve injury-induced mechanical allodynia and MAPK signaling by activating ISG15 in mouse spinal cord.[J]. J Pain,2020;21(7-8):836-847.
[16] Buda G, Valdez RM, Biagioli G, et al.Inflammatory cutaneous lesions and pulmonary manifestations in a new patient with autosomal recessive ISG15 deficiency case report[J]. Allergy Asthma Clin Immunol,2020,16(1):77.
[17] Swaim CD, Canadeo LA, Monte KJ, et al.Modulation of extracellular ISG15 signaling by pathogens and viral effector proteins[J]. Cell Rep,2020,31(11):107772.
[18] Desai SD, Wood LM, Tsai YC, et al.ISG15 as a novel tumor biomarker for drug sensitivity[J]. Mol Cancer Ther, 2008,7(6):1430.
[19] Zhou S, Ren M, Xu H, et al.Inhibition of ISG15 enhances the anti-cancer effect of trametinib in colon cancer cells[J]. Onco Targets Ther,2019,26(12):10239-10250.
[20] Yi H, Zong Z, Wang Q, et al.ISG15 silencing increases cisplatin resistance via activating p53-mediated cell DNA repair[J]. Oncotarget,2017,8(64):107452-107461.
[21] Chen RH, Xiao ZW, Yan X Q, et al.Tumor cell-secreted ISG15 promotes tumor cell migration and immune suppression by inducing the macrophage M2-like phenotype[J]. Front Immunol, 2020,23(11):594775.
[22] Chen RH, Yong D, Ping H, et al.ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma[J]. Oncotarget, 2016,7(13):16910-16922.
[23] Kong EB, Kim HD, Kim J.Deleting key autophagy elongation proteins induces acquirement of tumor-associated phenotypes via ISG15[J]. Cell Death Differ, 2020,27(8):2517-2530.
[24] Alcalá S, Sancho P, Martinelli P, et al.ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity[J]. Nat Commun,2020,11(1):2682.
[25] Sun J, Yan J, Qiao H Y, et al.Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation[J]. Oncogene.2020,39(3):546-559.
[26] Sainz B, Martin B, Tatari M, et al.ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells[J]. Cancer Res, 2014,74(24):7309-20.
[27] Bektas N, Noetzel E, Veeck J, et al.The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer[J]. Breast Cancer Res, 2008, 10(4): R58.
[28] Desai SD, Reed RE, Burks J, et al.ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells[J]. Adv Exp Med Biol,2012,237(1):38-49.
[29] Tecalco-Cruz A, Cortes-Gonzalez CC, Cruz-Rams Z, et al.Interplay between interferon-stimulated gene 15/ISGylation and interferon gamma signaling in breast cancer cells[J]. Cell Signal, 2019,2(54):91-101.
[30] Forys J, Kuzmicki C, Saporita A, et al.ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis[J]. Cell Rep, 2014 ,7(2):514-526.
[31] Wood L M, Pan ZK, Seavey MM, et al.The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy[J]. Cancer Immunol Immun, 2012,61(5):689-700.
[32] Burks J, Reed RE, Desai SD.Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective[J]. Oncotarget, 2015,6(9):7221-7231.